Overexpression of HER2 has been observed in many cancers, most notably breast cancer, wherein 30% of breast cancers exhibted a two to twenty-fold increase in gene amplification, correlating with higher recurrence rates and shorter overall survival times for patients [3, 4]. The gene discussed is ERBB2; the disease is breast carcinoma.